乳腺癌化疗后骨质疏松：一例报告
Osteoporosis after breast cancer chemotherapy: a case report.
作者信息
Sisti Giovanni, Prontera Olga
出版信息
Ochsner J. 2009 Summer;9(2):68-74.
Abstract
We describe therapeutic challenges in a patient with breast cancer during follow-up after quadrantectomy. The patient had used hormone therapy for 5 years and then tamoxifen citrate, a selective estrogen receptor modulator, for 3 years. When seen by us, she was taking Arimidex, an aromatase inhibitor. In accord with recommendations in the literature, bisphosphonate therapy was prescribed by clinicians at the Menopause Center in cooperation with the Oncology Center. We suggest that cooperation between menopause centers and oncology centers should continue in the follow-up of such patients.
摘要
我们描述了一位乳腺癌患者在象限切除术后随访期间所面临的治疗挑战。该患者已接受了5年的激素治疗，随后又服用了3年的枸橼酸他莫昔芬（一种选择性雌激素受体调节剂）。我们见到她时，她正在服用芳香化酶抑制剂阿那曲唑。根据文献中的建议，更年期中心的临床医生与肿瘤中心合作，为她开了双膦酸盐治疗。我们建议，在对此类患者的随访中，更年期中心和肿瘤中心应继续合作。
相似文献
1
Osteoporosis after breast cancer chemotherapy: a case report.乳腺癌化疗后骨质疏松：一例报告
Ochsner J. 2009 Summer;9(2):68-74.
2
Emerging bone health issues in women with breast cancer in Hawai'i.夏威夷乳腺癌女性中出现的骨骼健康问题。
Hawaii Med J. 2007 Jun;66(6):164-6.
3
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.辅助性他莫昔芬或阿那曲唑治疗后转移性乳腺癌的序贯激素治疗
Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. doi: 10.1023/a:1025459232293.
4
Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.绝经前和绝经后近期激素受体阳性乳腺癌患者的辅助内分泌治疗。
Clin Breast Cancer. 2014 Jun;14(3):147-53. doi: 10.1016/j.clbc.2013.12.010. Epub 2013 Dec 27.
5
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.美国临床肿瘤学会关于芳香化酶抑制剂作为激素受体阳性绝经后乳腺癌妇女辅助治疗的技术评估：2004年现状报告
J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15.
6
7
Emerging role of aromatase inhibitors in the adjuvant setting.芳香化酶抑制剂在辅助治疗中的新作用。
Am J Clin Oncol. 2003 Aug;26(4):S27-33. doi: 10.1097/00000421-200308001-00005.
8
Osteopenia and osteoporosis in women with breast cancer.乳腺癌女性中的骨质减少和骨质疏松
Semin Oncol. 2003 Dec;30(6):763-75. doi: 10.1053/j.seminoncol.2003.08.028.
9
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.在一般社区环境下，辅助他莫昔芬和芳香酶抑制剂治疗与美国乳腺癌女性对侧乳腺癌风险的关系。
JAMA Oncol. 2017 Feb 9;3(2):186-193. doi: 10.1001/jamaoncol.2016.3340. Epub 2016 Oct 6.
10
Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.激素治疗与乳腺癌幸存者的骨质疏松症：风险评估及对筛查建议的依从性。
Osteoporos Int. 2019 Jan;30(1):187-200. doi: 10.1007/s00198-018-4758-4. Epub 2018 Nov 9.
本文引用的文献
1
Diagnosis and treatment of advanced breast cancer: summary of NICE guidance.
BMJ. 2009 Feb 25;338:b509. doi: 10.1136/bmj.b509.
2
The effect of aromatase inhibitors on bone metabolism.芳香化酶抑制剂对骨代谢的影响。
Basic Clin Pharmacol Toxicol. 2009 Jan;104(1):3-10. doi: 10.1111/j.1742-7843.2008.00337.x.
3
Aromatase inhibitors and bone health.芳香化酶抑制剂与骨骼健康。
Curr Opin Obstet Gynecol. 2009 Feb;21(1):60-7. doi: 10.1097/GCO.0b013e32831da80e.
4
Prospective evaluation of risk factors for male breast cancer.男性乳腺癌风险因素的前瞻性评估。
J Natl Cancer Inst. 2008 Oct 15;100(20):1477-81. doi: 10.1093/jnci/djn329. Epub 2008 Oct 7.
5
Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.乳腺癌检测丑闻将聚光灯投向临床实验室检测的黑匣子。
J Natl Cancer Inst. 2008 Jun 18;100(12):836-7, 844. doi: 10.1093/jnci/djn200. Epub 2008 Jun 10.
6
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.乳腺癌治疗引起的骨质流失管理指南：英国专家组的共识立场声明
Cancer Treat Rev. 2008;34 Suppl 1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2.
7
Gene expression profiles in breast cancer to identify estrogen receptor target genes.乳腺癌中的基因表达谱以鉴定雌激素受体靶基因。
Mini Rev Med Chem. 2008 May;8(5):448-54. doi: 10.2174/138955708784223503.
8
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.通过雌激素受体、孕激素受体和人表皮生长因子受体2来近似划分的乳腺癌亚型与保乳治疗后的局部和远处复发相关。
J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14.
9
Aromatase inhibitors in the management of early breast cancer.芳香化酶抑制剂在早期乳腺癌治疗中的应用
Eur J Surg Oncol. 2008 Nov;34(11):1199-207. doi: 10.1016/j.ejso.2008.02.005. Epub 2008 Mar 21.
10
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.可视化破骨细胞和非吸收细胞对双膦酸盐的矿物质结合及摄取情况。
Bone. 2008 May;42(5):848-60. doi: 10.1016/j.bone.2007.12.225. Epub 2008 Jan 26.
Zotero 插件